RT Journal Article SR Electronic T1 PARP Inhibitors in Prostate Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 551 OP 556 DO 10.21873/anticanres.14807 VO 41 IS 2 A1 KABIR GREWAL A1 KAYANAAT GREWAL A1 IMAD A. TABBARA YR 2021 UL http://ar.iiarjournals.org/content/41/2/551.abstract AB Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in the outcome of patients with metastatic prostate cancer who harbor certain genetic mutations. This concise review focuses on the 3 PARP inhibitors that have shown activity in metastatic prostate cancer.